Their drug is an IL-1β inhibitor which addresses one part of the inflammation equation just like GM-CSF and IL-6 inhibitors. I have my doubts that the FDA realizes the much broader action of CCR5 blockade. Leronlimab's trial results will prove it out but it would be nice to have cytokine testing to bolster it.